Mallinckrodt Establishes Uveitis Research Fellowship

MNK_ARVOFellowshipAnnouncement_Twitter_800x418_Logos

As a company committed to managing complexity to help advance treatments for critical and severe illnesses like uveitis, we’re proud to support research of inflammatory eye disorders in partnership with the Association for Research in Vision and Ophthalmology (ARVO), the world’s largest eye and vision research organization. The newly established Mallinckrodt Uveitis Research Fellowship will support an early-career investigator to explore the causes and components of uveitis and similar disorders in novel ways.

“Uveitis is severe and debilitating and further research is vital to helping an often-underserved patient community,” said Tunde Otulana, M.D., Senior Vice President and Chief Medical Officer at Mallinckrodt. “Mallinckrodt is honored to partner with the ARVO Foundation to fund vital and potentially life-changing research as part of our continued commitment to critical ophthalmology conditions.”

The fellowship supports scientific discovery that seeks to better understand uveitis and other inflammatory eye conditions, their causes and treatments that will benefit different patient populations. This important work builds on a foundation of knowledge that practitioners can ultimately use to manage symptoms with the goal of helping to prevent vision loss for their patients.

A rare and often devastating inflammatory eye disorder, uveitis impacts both adults and children and can lead to loss of vision, accounting for up to 20 percent of legal blindness in the United States.[i] Vision impairment can impact nearly every aspect of daily life, often threatening a person’s independence, well-being and limiting daily activities, work and social interactions.

Uveitis can be caused by autoimmune or inflammatory disease, infection or injury that damages tissue in the eye, and managing the condition can be complex since the origin is sometimes unknown. Treatments are available that can halt progression of the disease, but not everyone can access or tolerate therapies and patients can lose their vision quickly. With so much at stake, more needs to be done for this often-underserved patient population. Research into the causes and treatments of ophthalmic disorders that can compromise vision and quality of life are greatly needed to help improve outcomes for patients.

We’re proud to support the ophthalmology research community, whose scientific collaboration advances understanding of rare eye diseases like uveitis and can ultimately elevate the care that patients receive.

More information on the Mallinckrodt Uveitis Research Fellowship and qualifications to apply can be found here.

Mallinckrodt, the “M” brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company.© 2019 Mallinckrodt. US-1900418 04/19

 

[i] Miserocchi E, Fogliato G, Modorati G, et al. Review on the worldwide epidemiology of uveitis. Eur J Ophthalmol. 2013;23(5):705-717. doi:10.5301/ejo.5000278.